EGFR mutation-positive NSCLC tumors are highly heterogeneous. therefore. exploring an agent simultaneously targeting multiple EGFR mutations may be valuable for clinical practice. Compared with osimertinib. https://www.chiggate.com/shades-eq-gloss-07m-driftwood-for-sale/